Proactive investorsLogo Proactive Investors UK Website

Search field
Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: QRX
News: Latest news
Web Site: QRxPharma Ltd
Other Articles: 10-12-200913-11-200912-10-2009

RSS - Subscribe to the News Today on Proactive UK ▼

Tuesday February 09, 07:53Mediterranean Oil & Gas doubles proven and probable reserves for Ombrina Mare to 40 mmbbls

The good news gave a welcome boost to the group's share price, sending the stock up nearly 15 percent in early trade.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Tuesday February 09, 11:07Randgold Resources remains focused on 1 million ounce production target

Speaking to assembled analysts in London, Randgold Resources CEO, Mark Bristow, told of a ‘great year' for his company, albeit also a challenging one, but one which would position it well for the years ahead

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Tuesday February 09, 01:53Chindex International reports increasing medical and healthcare revenues

Healthcare products and services group Chindex International (NASDAQ: CHDX) reported increasing revenues as it continued to expand its operations in the People’s Republic of China (PRC).

FULL ARTICLE ►
QRxPharma Ltd

QRxPharma Ltd

QRxPharma Limited (ASX: QRX; OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders.  The Company’s lead products comprise a patented combination of existing drugs, with a well-defined path to regulatory approval and sales.  QRxPharma’s lead drug compound, MoxDuo™ IR (Q8003IR), began Phase III clinical trials in November 2007. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics.

 

CLICK HERE FOR FULL ANLAYSIS OF QRXPHARMA LTD
Tuesday, August 25, 2009

QrxPharma's MoxDuo™ IR drug demonstrates fewer side effects than Percocet in trial

company news image

With cash reserves of $17 million for product development, QRxPharma's (ASX: QRX and OTCQX: QRXPY) lead compound, MoxDuo™ IR, has demonstrated fewer side effects than Percocet® in Phase 3 Pilot Studies.  This follows a recent Phase 3 MoxDuo™ IR study, which indicated that MoxDuo™ IR provided better tolerability than morphine and oxycodone alone.

In the latest pilot study, MoxDuo™ IR capsules were given to patients with moderate to severe pain following total knee replacement surgery. When compared at equianalgesic doses with Percocet®, the second most widely prescribed opioid in the US, MoxDuo™ IR demonstrated greater overall tolerability with substantially fewer side effects than Percocet®.

The size of the market that MoxDuo™ IR will enter in 2011 is significant.  MoxDuo™ IR targets the acute pain market; a $2.5 billion segment of the $7 billion spent annually on prescription opioids in the US.

To date, more than 400 patients in six clinical trials have received MoxDuo™ IR for different forms of post‐surgical pain (bunionectomy and total knee replacement). Study results with MoxDuo™ IR consistently demonstrate fewer side effects than observed with morphine alone, oxycodone alone and now with Percocet®.

Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma believes that MoxDuo™ IR will significantly improve patient care, providing equal or better analgesia with fewer and/or less intense side effects than current standards of care.

AddThis Feed Button
Register here to be notified of future QRxPharma Ltd articles.

Other QRxPharma Ltd articles


Other QRxPharma Ltd news

More news ►

Investors interested in QRxPharma Ltd recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.